<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02521883</url>
  </required_header>
  <id_info>
    <org_study_id>T248/2014</org_study_id>
    <nct_id>NCT02521883</nct_id>
  </id_info>
  <brief_title>Transcranial Direct Current Stimulation (tDCS) as an add-on Therapy for Treatment of Major Depressive Disorder. (DEPTDCS2014)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sooma Oy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to investigate the safety and effectiveness of transcranial Direct Current
      Stimulation (tDCS) in patients with moderate to severe major depression compared to patients
      treated with conventional therapy. The tDCS will be used as add-on to conventional therapy.

      This is a randomized 2-arm parallel, double blind study comparing 2 groups of 60 patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Montgomery-Åsberg depression scale (MADRS)</measure>
    <time_frame>baseline, wk 2, wk 4, wk 5, wk 6, 3 months, 6 months</time_frame>
    <description>Efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dichotomised response measured with MADRS.</measure>
    <time_frame>baseline, wk 2, wk 4, wk 5, wk 6, 3 months, 6 months</time_frame>
    <description>Response to treatment is defined as a ≥ 50% reduction in the MADRS baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Beck Depression Inventory (BDI) scale.</measure>
    <time_frame>baseline, wk 2, wk 4, wk 5, wk 6, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dichotomised remission measured with MADRS.</measure>
    <time_frame>baseline, wk 2, wk 4, wk 5, wk 6, 3 months, 6 months</time_frame>
    <description>Remission is defined as a MADRS score ≤ 10.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Device: Sooma tDCS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The active group will receive active Sooma tDCS treatment for the first three weeks followed by maintenance treatments at weeks 5 and 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Device: Sham tDCS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo group will receive sham tDCS treatment for the first three weeks followed by sham maintenance treatments at weeks 5 and 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sooma tDCS</intervention_name>
    <description>2mA current applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).</description>
    <arm_group_label>Device: Sooma tDCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham tDCS</intervention_name>
    <description>sham stimulation (current phased off after 20 secs) applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).</description>
    <arm_group_label>Device: Sham tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfils the ICD-10 diagnostic criteria for moderate or severe major depressive episode
             (F32), or recurrent major depressive episode (F33)

          -  Able to understand the purpose and potential risks of the study

          -  Able to sign informed consent

        Exclusion Criteria:

          -  intracranial metal implants or other foreign intracranial metal object

          -  history of neurological conditions e.g. epilepsy, stroke (ischemic or haemorrhagic);
             brain tumor; increased intracranial pressure etc.

          -  schizophrenia

          -  bipolar disorder

          -  psychotic disorder

          -  substance abuse or dependency

          -  contra-indications to tDCS

          -  personality disorder that may prevent him/her to commit to the study

          -  skin lesion in the area of stimulation

          -  planned treatment of current depressive episode with ECT or rTMS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tero Taiminen, MD, docent</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tero Taiminen, MD, docent</last_name>
    <phone>+358-2-3131741</phone>
    <email>tero.taiminen@tyks.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>PHSOTEY, Psykiatrian tulosalue, ECT-yksikkö</name>
      <address>
        <city>Lahti</city>
        <zip>15850</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikko Pänkäläinen, MD</last_name>
      <phone>+358-3-8192952</phone>
      <email>mikko.pankalainen@phsotey.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VSSHP Psykiatria, Liedon aikuispsykiatrian poliklinikka</name>
      <address>
        <city>Lieto</city>
        <zip>21420</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Denissoff, MD</last_name>
      <phone>+358-2-3145970</phone>
      <email>alexander.denissoff@tyks.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tero Taiminen, MD, docent</last_name>
      <phone>+358-2-3131741</phone>
      <email>tero.taiminen@tyks.fi</email>
    </contact>
    <investigator>
      <last_name>Tero Taiminen, MD, docent</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sektionen för affektiva sjukdomar, Norra Stockholms Psykiatri, Stockholms läns sjukvårdsområde</name>
      <address>
        <city>Stockholm</city>
        <state>Stockholms län</state>
        <zip>10233</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Lundberg, MD</last_name>
      <phone>+46 72 560 84 67</phone>
      <email>johan.lundberg@sll.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2015</study_first_submitted>
  <study_first_submitted_qc>August 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

